Welcome to Arctom, sign up to enjoy up to 20% OFF

Search in Small Molecules Search in Biologics

Structure Search

Cart - 0 item(s)
$0.00

Your shopping cart is empty!

Chemistry
Inhibitors
- Anti-infection
Natural Products
ADCs
Antibodies
Multiplex IHC
Material Science
Others

[CAS NO. 78439-06-2] Ceftazidime pentahydrate

Ships within

Stock

Price

Qty

Total

SDS

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-B0593A
Brand:	MCE
CAS:	78439-06-2

Overview

MDL	MFCD00153936
Molecular Weight	636.65
Molecular Formula	C22H32N6O12S2
SMILES	O=C1[C@@H](NC(/C(C2=CSC(N)=N2)=N\OC(C)(C(O)=O)C)=O)[C@@]3([H])SCC(C[N+]4=CC=CC=C4)=C(C([O-])=O)N13.[5H2O]

For research use only. We do not sell to patients.

12 Publications Citing Use of MCE

[1]Adv Sci (Weinh). 2020 Jul 21;7(17):2001374.
[2]Nat Commun. 2022 Mar 2;13(1):1116.
[3]J Antimicrob Chemother. 2022 Jul 15;dkac232.
[4]J Antimicrob Chemother. 2020 Sep 1;75(9):2609-2615.
[5]J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858.
[6]Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00414-18.
[7]Int J Antimicrob Agents. 2018 Aug;52(2):269-271.
[8]Sci Rep. 2022 Oct 7;12(1):16814.
[9]BMC Microbiol. 2020 Jun 29;20(1):187.
[10]Infect Drug Resist. 2021 Jun 30;14:2499-2507.
[11]J Antibiot (Tokyo). 2023 Feb 1.
[12]Patent. US20200101105A1.

Summary

Ceftazidime (GR20263) pentahydrate , an antibiotic , has a broad spectrum activity against Gram-positive and Gram-negative aerobic bacteria. Ceftazidime pentahydrate is also active against Enterobacteriaceae (including β-lactamase-positive strains) and is resistant to hydrolysis by most β-lactamases ^[1] .

In Vitro

Ceftazidime (0-8 µg/mL approximately, 24 h) pentahydrate displays antibacterial and anti-biofilm activities against P. aeruginosa strains ^[2] .
Ceftazidime (0-40 µg/mL approximately, 18-20 h) pentahydrate has inhibitory activities against S. maltophilia isolates ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay ^[2]

Cell Line:	P. aeruginosa strains (PAO1, PA1, PA2)
Concentration:	0-8 µg/mL approximately
Incubation Time:	24 h
Result:	Displayed antibacterial and anti-biofilm activities with MIC values of 2-4 µg/mL.

In Vivo

Ceftazidime (2 h infusion of injection, 2 000 mg, every 8 h for 24 h) pentahydrate moderately reduces bacterial density in a murine thigh infection model ^[4] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Murine thigh infection model ^[4]
Dosage:	2000 mg
Administration:	2 h infusion of injection, every 8 h for 24 h.
Result:	Reduced bacterial density against the isogenic NDM (New Delhi metallo-β-lactamase) strain.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00210899	Basilea Pharmaceutica	Skin Diseases, Infectious\|Skin Diseases, Bacterial\|Staphylococcal Skin Infections	September 2005	Phase 3
NCT04402359	King Abdul Aziz Specialist Hospital	Ventilator Associated Pneumonia	July 5, 2018
NCT00752882	University Hospital, Clermont-Ferrand	Pseudomonas Aeruginosa Meningitis		Phase 2
NCT05105035	Arrevus Inc.\|Aceragen	Melioidosis	June 14, 2022	Phase 2
NCT00195923	Children´s Mercy Hospital Kansas City	Perforated Appendicitis	April 2005
NCT04771884	Shandong University\|Children´s Hospital of Chongqing Medical University	Bacterial Meningitis\|Augmented Renal Clearance	October 1, 2020
NCT01344512	University Hospital, Bordeaux	Pediatrics\|Ceftazidime\|Ciprofloxacin\|Voriconazole	June 2011	Not Applicable
NCT02497781	Pfizer\|PRA Health Sciences	Complicated Urinary Tract Infections	September 24, 2015	Phase 2
NCT01455246	University of Padova	Cirrhosis\|Ascites\|Nosocomial Spontaneous Bacterial Peritonitis	October 2010	Phase 2\|Phase 3
NCT03754387	Zunyi Medical College	Chronic Appendicitis	January 1, 2019	Not Applicable
NCT04948463	Murdoch Childrens Research Institute	Febrile Neutropenia	November 15, 2021	Phase 4
NCT00823238	University of North Carolina, Chapel Hill\|Cystic Fibrosis Foundation	Cystic Fibrosis	July 2004	Phase 1
NCT01595438	Pfizer\|Forest Laboratories	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	October 2012	Phase 3
NCT02840136	University Ghent\|King Baudouin Foundation\|Belgische Vereniging voor Strijd tegen Mucoviscidose	Cystic Fibrosis	February 2016	Not Applicable
NCT01784445	University Hospital Rijeka	Pancreatitis	June 2013	Phase 4
NCT00579956	University of Oxford\|Mahidol University\|Wellcome Trust	Melioidosis	December 2007	Not Applicable
NCT00921024	Cubist Pharmaceuticals LLC	Complicated Urinary Tract Infection	June 30, 2009	Phase 2
NCT00786305	Groupe Hospitalier Pitie-Salpetriere	Pneumonia	October 2004	Phase 2
NCT00210964	Basilea Pharmaceutica	Pneumonia	April 2005	Phase 3
NCT01044719	Imperial College London	Cystic Fibrosis	January 2010	Phase 4
NCT01599806	Pfizer\|Forest Laboratories	Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis	October 2012	Phase 3
NCT02837835	CHU de Reims	Pneumonia	March 2005	Phase 3
NCT02787057	Peking University First Hospital	Peritoneal Dialysis Associated Peritonitis	November 2012	Not Applicable
NCT01785641	Chulalongkorn University	Peritonitis	December 2012	Not Applicable
NCT01290900	Pfizer	Healthy Male Volunteers	February 2011	Phase 1
NCT04961580	Children´s Hospital of Fudan University	Sepsis\|Antibiotic Reaction	December 1, 2022
NCT01644643	Pfizer\|Forest Laboratories	Complicated Urinary Tract Infection\|Complicated Intra-abdominal Infection	January 2013	Phase 3
NCT00153634	Seattle Children´s Hospital\|Cystic Fibrosis Foundation	Cystic Fibrosis\|Chronic Bronchitis	March 2004	Not Applicable
NCT01667094	The Alfred	Cystic Fibrosis	September 2012	Phase 4
NCT04187755	Indonesia University	Neutropenia, Febrile\|Leukemia\|Pediatric Cancer\|Antibiotic Reaction	March 1, 2019	Phase 4
NCT00333385	Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche\|Vaincre la Mucoviscidose\|GlaxoSmithKline\|Baxter Healthcare Corporation\|Roche Pharma AG	Cystic Fibrosis\|Pseudomonas Aeruginosa\|Pulmonary Exacerbation	October 2001	Phase 4
NCT02526004	University College Cork\|Queen´s University, Belfast\|University of Paris 5 - Rene Descartes\|University of Dundee\|University of Washington\|University Hospital Heidelberg\|Teagasc\|Clininfo S.A.\|GABO:mi\|Papworth Hospital NHS Foundation Trust\|KU Leuven\|Assistance Publique - Hôpitaux de Paris\|European Union	Cystic Fibrosis	October 1, 2013	Not Applicable
NCT05487586	Pfizer	Hospital Acquired Pneumonia\|Ventilator Acquired Pneumonia\|Complicated Intra Abdominal Infections	October 18, 2022
NCT00173901	National Taiwan University Hospital	Infection	March 2001	Phase 4
NCT04319328	University of Manitoba\|The Kidney Foundation of Canada	Hemodialysis Complication\|Infectious Disease\|End Stage Renal Disease	October 18, 2019
NCT00229008	Basilea Pharmaceutica	Pneumonia	November 2005	Phase 3
NCT02872038	Chulalongkorn University\|The Kidney Foundation of Thailand\|Siam Pharmaceutical Co Ltd	Peritoneal Dialysis Associated Peritonitis	August 2015	Phase 4
NCT03404739	Shanghai Zhongshan Hospital	Esophageal Achalasia	October 1, 2017	Phase 2\|Phase 3
NCT03376529	Spero Therapeutics\|Simbec Research\|QPS	Healthy Volunteers	November 10, 2017	Phase 1
NCT02475733	Pfizer	Complicated Intra-abdominal Infections	August 1, 2015	Phase 2
NCT01430910	Pfizer	Healthy	September 2011	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL ( 157.07 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5707 mL	7.8536 mL	15.7072 mL
5 mM	0.3141 mL	1.5707 mL	3.1414 mL
10 mM	0.1571 mL	0.7854 mL	1.5707 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: 2.5 mg/mL (3.93 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 2.5 mg/mL (3.93 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Richards DM, et al. Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs. 1985 Feb;29(2):105-61.
[2] Esmat Kamali, et al. In vitro activities of cellulase and ceftazidime, alone and in combination against Pseudomonas aeruginosa biofilms. BMC Microbiol. 2021 Dec 16;21(1):347.
[3] Qiuxia Lin, et al. Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro. BMC Microbiol. 2021 Feb 22;21(1):60.
[4] Shawn H MacVane, et al. Unexpected in vivo activity of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-lactamase-producing Enterobacteriaceae in a murine thigh infection model. Antimicrob Agents Chemother. 2014 Nov;58(11):7007-9.

Synonyms

Pyridinium, 1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, hydrate (1:5)

Pyridinium, 1-[[7-[[(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, pentahydrate, [6R-[6α,7β(Z)]]-

Pyridinium, 1-[[(6R,7R)-7-[[(2Z)-(2-amino-4-thiazolyl)[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-, inner salt, pentahydrate

Ceftazidime pentahydrate

Glazidim

Starcef 1

Cefidime

Ceftadizim

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart